Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.

Torgersen, Jessie; Newcomb, Craig W; Carbonari, Dena M; Rentsch, Christopher T; Park, Lesley S; Mezochow, Alyssa; Mehta, Rajni L; Buchwalder, Lynn; Tate, Janet P; Bräu, Norbert; +5 more... Bhattacharya, Debika; Lim, Joseph K; Taddei, Tamar H; Justice, Amy C; Lo Re, Vincent; (2021) Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal of Hepatology, 75 (6). pp. 1312-1322. ISSN 0168-8278 DOI: https://doi.org/10.1016/j.jhep.2021.07.021

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/j.jhep.2021.07.021

Abstract

Share

Download

Embargo Date: 29 July 2022

Restricted to: Repository staff only

Filename: Torgersen_etal_2021_Protease-inhibitor-based-direct-acting.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

[img]

Downloads

View details

Metrics & Citations


Google Scholar